Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Weight Gain From Atypical Antipsychotics Returns To FDA Advisory Cmte.

This article was originally published in The Pink Sheet Daily

Executive Summary

Panel urged label changes two years ago, but the products still do not include uniform information in their warning sections. FDA is asking its Pediatric Advisory Committee to review the pediatric safety of Bristol/Otsuka's Abilify, along with an AHRQ report on weight gain associated with the class of products.
Advertisement

Related Content

Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
Atypical Antipsychotics To Add Warning About Metabolic Effects In Kids
Atypical Antipsychotics To Add Warning About Metabolic Effects In Kids

Topics

Advertisement
UsernamePublicRestriction

Register

PS072708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel